CELL EXPANSION MARKET ANALYSIS

Cell Expansion Market, by Product (Consumables, (Media, Others), Instruments (Automated Cell, Expansion Systems, Cell Counters, Centrifuges, Bioreactors, Others), Accessories), by Cell Type (Mammalian Cells, (Human Cells, Stem Cells, Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells), Differentiated Cells, Animal Cells), Microbial Cells, Others (Plant-derived Cells)), by Application (Biopharmaceuticals, Tissue Culture & Engineering, Vaccine Production, Drug Development, Cancer Research, Stem Cell Research, Other Applications), by End User (Biotechnology Companies, Biopharmaceutical Companies, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024
Code : CMI1293
Pages :402
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Cell Expansion Market – Regional Analysis

On the basis of region, the global cell expansion market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America cell expansion market is expected to hold a dominant position during the forecast period, owing to the increasing acquisition by market players of cell and gene therapy manufacturing facilities in the region. For instance, in July 2021, AGC Biologics, a major global biopharmaceutical contract development and manufacturing organization (CDMO), signed a purchase agreement with Novartis Gene Therapies, a division of Novartis AG to acquire a state-of-the-art cell and gene therapy commercial manufacturing facility in Longmont, Colorado, U.S. The facility will provide AGC Biologics with significant extra capacity and space, pending full due diligence, to continue to develop its end-to-end Cell and Gene Therapy (C&GT) offering, assuring supply security for current and future C&GT clients.

Furthermore, Europe is expected to exhibit significant growth in the cell expansion market, owing to increasing facility expansion and investment in cell and gene therapy manufacturing by market players in this region. For instance, in March 2021, GSK, a science-led global healthcare company, announced the agreement with Cell and Gene Therapy Catapult, a non-profit organization dedicated to the improvement of cell and gene therapies through creativity and technology, to expand its clinical trial manufacturing capacity for cell and gene therapy at the Cell and Gene Therapy Catapult facility in Stevenage, U.K.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa